We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
201
Milestone Pharmaceuticals
MIST
$143M
$392K 0.02%
213,310
-533,343
-71% -$9.23M
NVAX icon
202
Novavax
NVAX
$1.27B
$388K 0.02%
28,550
– –
CLSD
203
DELISTED
Clearside Biomedical
CLSD
$281K 0.01%
11,022
– –
SPPI
204
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$267K 0.01%
114,670
– –
MRUS
205
DELISTED
Merus
MRUS
$257K 0.01%
21,215
– –
TPTX
206
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$254K 0.01%
5,677
– –
WHWK
207
Whitehawk Therapeutics
WHWK
$201M
$142K 0.01%
17,170
– –
CBAY
208
DELISTED
Cymabay Therapeutics
CBAY
$130K 0.01%
88,102
– –
DNTH icon
209
Dianthus Therapeutics
DNTH
$6.29B
$105K ﹤0.01%
1,047
– –
ORKA
210
Oruka Therapeutics
ORKA
$5.86B
$100K ﹤0.01%
3,006
– –
ALR
211
DELISTED
AlerisLife Inc
ALR
$67K ﹤0.01%
+24,237
New +$102K
MNK
212
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$65K ﹤0.01%
32,980
– –
TTPH
213
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$55K ﹤0.01%
42,965
– –
BLCM
214
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$28K ﹤0.01%
6,000
– –
VIE
215
DELISTED
Viela Bio, Inc. Common Stock
VIE
$19K ﹤0.01%
+500
New +$19.5K
CLDX icon
216
Celldex Therapeutics
CLDX
$3.22B
$12K ﹤0.01%
7,053
– –
QHC
217
DELISTED
Quorum Health Corporation
QHC
$11K ﹤0.01%
23,725
– –
ADAP
218
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-77,061
Closed -$92K
IBB icon
219
iShares Biotechnology ETF
IBB
$9.47B
– –
-38,834
Closed -$4.68M
MASI
220
DELISTED
Masimo
MASI
– –
-21,773
Closed -$3.44M
MYGN icon
221
Myriad Genetics
MYGN
$301M
– –
-18,805
Closed -$512K
XBI icon
222
State Street SPDR S&P Biotech ETF
XBI
$9.99B
– –
-68,037
Closed -$6.47M
XENE icon
223
Xenon Pharmaceuticals
XENE
$6.19B
– –
-96,961
Closed -$1.27M
FOMX
224
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-300,781
Closed -$1M
DERM
225
DELISTED
Dermira, Inc.
DERM
– –
-89,200
Closed -$1.35M
6 7 8
9
10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.